Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients

Noninvasive Diagnosis of Liver Fibrosis and Cirrhosis in Chronic Hepatitis C Patients

“…Platelet count has been combined with age in the age‐platelet index or with AST/ALT ratio and prothrombin time in the cirrhosis discriminant scores . In addition, platelet count is a component of APRI , Fibro‐α , Forns index , model 3 , Fibrometer , and Fibroindex . In the present study, AFP was the most efficient marker among other markers with AUC of 0.79 for identifying patients with significant liver fibrosis.…”

“…APRI was calculated as [(AST/upper limit of normal) / platelet count (10 9 /l)] × 100. Fibro‐α score was calculated as 1.35 + AFP (U/l) × 0.009584 + AAR × 0.243 –platelet count (10 9 /l) × 0.001624. King's score was calculated as age × AST (U/l) × INR/platelet count (10 9 /l).…”

Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study

“…Although there are several models described to predict severe liver fibrosis on the basis of laboratory parameters; either free to use like APRI (25) and Forns (23) or protected by patents like: the FibroTest (26), Fibrometers (27), FibroSpect (28), Enhanced Liver Fibrosis Test (ELF) (29, 30) and HepaScore (31); none of them have described the use of tumor markers for prediction of liver fibrosis, even recently developed models including: Fibro-α Score (16) and FibroSteps (17). Most of these models were validated in chronic hepatitis C; few are validated for other causes of chronic liver disease.…”

“…Although non-patented scores, such as the Forns index, FIB-4, and APRI may have slightly lower performances, they are cost-free, easy to calculate, and available almost everywhere (32). Fibro-α score predicts significant liver fibrosis (F2–F4) with 70% sensitivity and 60% specificity, advanced liver fibrosis (F3–F4) with 88% sensitivity and 60% specificity and liver cirrhosis (F4) with 90% sensitivity and 57% specificity (16). In a recent study, FibroSteps (17) could differentiate different stages of hepatic fibrosis with accuracies of 94.9% and 89.8% in the training and validation sets, respectively.…”

“…Other widely used panels of biomarkers include: The AST-to-Platelet Ratio Index (APRI), FibroIndex (platelet count, AST, GGT), FibroMeter (platelet count, α2 macroglobulin, AST, age, prothrombin index, hyaluroinc acid (HA), blood urea nitrogen), Forns (age, platelet count, GGT, cholesterol levels), Hepascore (age, gender, bilirubin, GGT, HA, α2-macroglobulin) and Fib-4 (platelet count, ALT, AST, platelet count, age) (15). More recent biomarker panels include: Fibro-α score (alpha Feto-Protein, aspartate aminotransferase, aspartate aminotransferase/alanine aminotransferase and platelet count) (16) and FibroSteps (hyaluronic acid, TGF-β1, α2-macroglobulin, MMP-2, apolipoprotein-A1, urea, MMP-1, alpha-fetoprotein, haptoglobin, RBCs, haemoglobin and TIMP-1) (17). …”